Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells

Receptor tyrosine kinase (RTK) signaling pathways are frequently activated in cancer cells due to mutations of RTKs and/or their downstream signaling proteins such as KRAS and BRAF. About 40% colorectal cancers (CRCs) contain KRAS or BRAF mutant genes and are resistant to treatments with individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Qiaoling, Sun, Xiaoxiao, Guo, Hui, Yu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354887/
https://www.ncbi.nlm.nih.gov/pubmed/28002807
http://dx.doi.org/10.18632/oncotarget.14009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354887/
https://www.ncbi.nlm.nih.gov/pubmed/28002807
http://dx.doi.org/10.18632/oncotarget.14009

Ejemplares similares